Metraipolis › archive › dc_5d912e4bfb94

Real-world efficacy of stapokibart for severe olfactory dysfunction: early and sustained improvement independent of baseline type 2 inflammation status and… — Europe PMC PMID:42367767

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42367767
DOI
10.3389/fimmu.2026.1858283
License (as archived)
solo-consultazione
Archived
2026-10-31T14:19:52.788Z
SHA-256 of the archived text
b05ef502316d6c1c249983f88ab55d2ca26ac9ac7f863d2c239e0c0d1b6fe0f5
Stable URL of this page
https://metraipolis.com/documento/dc_5d912e4bfb94

How to cite

Real-world efficacy of stapokibart for severe olfactory dysfunction: early and sustained improvement independent of baseline type 2 inflammation status and… — Europe PMC PMID:42367767 — Europe PMC (en), https://europepmc.org/article/MED/42367767 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5d912e4bfb94 (Metraipolis archive dc_5d912e4bfb94, sha256 b05ef502316d6c1c249983f88ab55d2ca26ac9ac7f863d2c239e0c0d1b6fe0f5)
BibTeX
@misc{dc5d912e4bfb94,
  title = {Real-world efficacy of stapokibart for severe olfactory dysfunction: early and sustained improvement independent of baseline type 2 inflammation status and… — Europe PMC PMID:42367767},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42367767},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5d912e4bfb94; sha256 b05ef502316d6c1c249983f88ab55d2ca26ac9ac7f863d2c239e0c0d1b6fe0f5},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42367767. Agents can read the archived copy with the MCP tool read_document.